Denali Therapeutics financials
$20.81−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.3M |
| Gross profit | $3.5M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.3M |
| Gross margin | 97.4% | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$130.5M | -$137.4M | -$137.4M | -$137.4M | -$135.0M | -$145.6M | -$129.8M | -$123.2M | -$116.6M | -$132.3M | -$132.6M | -$113.8M |
| Net income | -$127.6M | -$129.8M | -$128.5M | -$126.9M | -$124.1M | -$133.0M | -$114.8M | -$107.2M | -$99.0M | -$101.8M | -$119.5M | -$99.4M |
| Net margin | −3539.2% | — | — | — | — | — | — | — | — | — | — | −7841.6% |
| Diluted EPS | $-0.68 | $-0.69 | $-0.73 | $-0.74 | $-0.72 | $-0.78 | $-0.67 | $-0.63 | $-0.59 | $-0.68 | $-0.89 | $-0.72 |
| EBITDA | -$127.0M | -$134.5M | -$134.5M | -$134.5M | -$131.9M | -$143.3M | -$128.0M | -$121.3M | -$104.1M | -$140.6M | -$132.6M | -$123.9M |
| Operating cash flow | -$97.0M | -$131.2M | -$98.5M | -$107.3M | -$75.3M | -$131.5M | -$83.7M | -$59.1M | -$91.2M | -$113.6M | -$98.7M | -$87.4M |
| Free cash flow | -$97.8M | -$133.7M | -$100.1M | -$108.7M | -$79.6M | -$136.5M | -$88.8M | -$63.0M | -$96.0M | -$115.8M | -$100.9M | -$89.4M |
| Diluted shares | 187.3M | 186.6M | 175.5M | 172.4M | 171.4M | 171.2M | 170.2M | 169.5M | 168.8M | 149.4M | 134.4M | 137.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $201.5M | $387.6M | $205.3M | $91.0M | $141.2M | $56.9M |
| Short-term investments | $508.9M | $600.1M | $662.6M | $757.2M | $757.7M | $761.0M |
| Total debt | $5.5M | $5.5M | $5.5M | $5.6M | $5.6M | $5.6M |
| Total assets | $1.16B | $1.27B | $1.14B | $1.06B | $1.17B | $1.27B |
| Total liabilities | $322.8M | $339.9M | $131.1M | $129.4M | $139.2M | $148.7M |
| Shareholders' equity | $835.2M | $926.1M | $1.01B | $926.2M | $1.03B | $1.12B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology